This document summarizes information from various presentations at a BioWin conference on advanced therapy medicinal products (ATMPs). It discusses the first approved ATMP in Europe by TiGenix in 2009 for cartilage repair, provides examples of Belgian companies developing ATMPs (TiGenix, Cardio3, Bone Therapeutics, Promethera), and highlights challenges in developing cell therapy products like maintaining cell viability over time and standardizing complex surgical and manufacturing processes.